KRRO.O (KRRO.O) News
Follow KRRO.O (KRRO.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Korro Bio: First cohort dosed in Phase 1/2 clinical trial for KRRO-121
Korro Bio has dosed the first cohort in its Phase 1/2 clinical trial (Anchor) for KRRO-121. Dosing in UCD patients is expected to start in H1 2027, with an interim readout in H2 2027.
EQUITY | Oct 05, 2026, 09:31 PM UTC
M
Korro Bio (KRRO.O) dosed first healthy volunteers in Phase 1/2 ANCHOR KRRO-121
Korro Bio dosed the first healthy-volunteer cohort in its Phase 1/2 ANCHOR trial of KRRO-121 for hyperammonemia; single 2 mg/kg dose, with interim readout expected in 2H 2027 and patient dosing expected in H1 2027.
EQUITY | Oct 05, 2026, 08:10 PM UTC